What is Radiopharmaceutical Therapy?
Radiopharmaceutical therapies (RPTs) are a new class of drugs that contain radioactive forms of chemical elements called radioisotopes that effectively diagnose and treat cancers.
Radiopharmaceuticals can be used as radioactive tracers in medical imaging to help improve disease diagnosis. RPTs also use tumour-targeting for small molecules, peptides, or biologics to deliver a cytotoxic payload that induces DNA damage in tumour cells, while limiting damage to normal and healthy tissue.
1 in 2 people will get cancer in their lifetime
Cancer is one of the world’s biggest killers and is forecast to increase in prevalence, with over 35 million new cancer cases predicted in 2050, a 77% increase from the estimated 20 million cases in 2022. Cancer outcomes in the UK lag significantly behind comparator countries and therefore, there is an urgent need to improve treatment and diagnosis.
Advances in Radiopharmaceutical Therapies for Cancer Treatments
Significant advances have been made in new treatments for cancer, including Stem Cell Therapies, Immunotherapy, DNA Sequencing, Personalised Vaccines, and now Radiopharmaceutical Therapy (RPT).
Medicines Discovery Catapult is pioneering the development, evaluation, and translation of radiopharmaceutical therapies to effectively diagnose and treat cancers. As a national Life Sciences service, our exceptional people combine their scientific, regulatory and operational expertise with the very best technology to deploy novel radiopharmaceutical therapies.
Preclinical Radiopharmaceutical Therapy Solutions
Bringing new therapeutic radiopharmaceuticals to the market is a complex and challenging process, we can provide preclinical solutions for your project.
Radiopharmaceutical Therapy Capabilities
Access our cutting-edge capabilities to ensure a smooth transition of your radiopharmaceutical into the clinic.
Related Pages
